LLY — Eli Lilly and Company

Summary of Eli Lilly Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue Growth: Q2 2026 revenue increased by 48% year-over-year, totaling approximately $85 billion to $87 billion for the full year.
• Key Products: Oncology, Immunology, and Neuroscience medicines grew collectively by 121%, contributing nearly $6.8 billion.
• Gross Margin: Gross margin was 86.3%, up 1.3 percentage points from Q2 2025, attributed to a favorable product mix and improved production costs.
• Non-GAAP Earnings Per Share: Reported at $8.38, compared to $6.31 in Q2 2025, reflecting a significant increase despite $3.03 in acquired IPR&D charges.
• Dividends and Share Repurchases: Distributed $1.5 billion in dividends and executed $1.6 billion in share repurchases.

2. Strategic Updates and Business Highlights

• Product Launches: The U.S. launch of Foundayo for obesity is gaining momentum, with direct-to-consumer marketing initiated. Foundayo is under regulatory review in over 40 countries.
• Regulatory Approvals: Key approvals include Ebglyss for atopic dermatitis maintenance dosing and Jaypirca for CLL in the EU.
• Acquisitions: Lilly expanded its pipeline through acquisitions, including companies focused on infectious diseases and mental health treatments.
• Medicare GLP-1 Bridge Program: Launched on July 1, providing coverage for 20 million eligible Americans, increasing access to anti-obesity medicines.

3. Forward Guidance and Outlook

• Revised Guidance: Full-year revenue guidance raised by $3 billion at the low end and $2 billion at the high end, now projected between $85 billion and $87 billion.
• Performance Margin: Expected non-GAAP performance margin adjusted to 49% to 50.5%.
• Earnings Per Share: Forecasted to be between $35.50 and $36.50, reflecting a $2.78 increase at the midpoint.

4. Bad News, Challenges, or Points of Concern

• Foundayo Launch Pace: The U.S. launch has been slower than anticipated, with competitive pressures from Novo's oral treatments affecting market dynamics.
• Price Declines: U.S. pricing for products has seen a decline due to adjustments in rebates and discounts, with expectations for continued pressure on pricing.
• Market Saturation: The obesity treatment market is still in early stages, with only mid-single-digit treatment rates, indicating a long road ahead for broader adoption.

5. Notable Q&A Insights

• Consumer Market Expansion: Executives discussed strategies to enhance consumer awareness and access to obesity treatments, highlighting the potential for significant growth as utilization rates are currently low.
• Foundayo Competitive Landscape: Concerns were raised about competitive dynamics in international markets, particularly with Novo's rapid market share gains.
• Retatrutide Regulatory Pathway: Ongoing discussions regarding the classification of retatrutide as a biologic, with expectations for a BLA submission by Q1 2027.
• Medicare Program Feedback: Positive early indicators from the Medicare GLP-1 Bridge program, with a significant portion of new patients being treated with injectables.

Overall, Eli Lilly reported strong financial performance and strategic advancements, while also navigating challenges in product launches and competitive pressures in the obesity treatment market. The company remains optimistic about future growth driven by its expanding pipeline and new product launches.